Clinical Trial Update: PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating preoperative immunotherapy combined with sacituzumab govitecan for muscle-invasive bladder cancer is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Fundación para el Progreso de la Oncología en Cantabria | Conditions: Urothelial Bladder Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING